Cathay International Holdings Ld 2017 Lansen Annual Results (0526J)
March 27 2018 - 3:59AM
UK Regulatory
TIDMCTI
RNS Number : 0526J
Cathay International Holdings Ld
27 March 2018
Cathay International Holdings Limited
("Cathay" or the "Company" or together with its subsidiaries,
the "Group")
Lansen reports annual results for the year ended 31 December
2017
Hong Kong, 27 March 2018 - Cathay International Holdings Limited
(LSE: CTI.L), an operator and investor in the growing healthcare
sector in the People's Republic of China, today notes Lansen
Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), the Company's
50.56% owned subsidiary, has reported its annual results for the
year ended 31 December 2017 in accordance with the requirements of
its Hong Kong listing.
The full text of the Lansen Announcement can be found at
http://www.hkexnews.hk/listedco/listconews/SEHK/2018/0327/LTN20180327373.pdf
and will also be made available at Announcements & Notices
section of Lansen's homepage at
http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.
As previously announced, Cathay will issue its Annual Results
for the year ended 31 December 2017 on Monday 9 April 2018.
-ENDS-
For further enquiries, please contact:
Cathay International Holdings Limited
Eric Siu (Finance Director) Tel: +852 2828 9289
Patrick Sung (Director and Controller)
Consilium Strategic Communications
Mary-Jane Elliott/ Matthew Neal / Lindsey Neville Tel: +44 (0)
203 709 5700
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and an operator and
investor in the growing healthcare sector in the People's Republic
of China (the "PRC"). The Company and its subsidiaries
(collectively the "Group") aim to leverage on growth opportunities
in the strong and growing domestic demand for high quality
healthcare products in the PRC and build its portfolio companies
into market sector leaders with competitive edge. Cathay has
already demonstrated a strong track record of identifying high
growth potential investment opportunities in this area including:
Lansen, a leading specialty pharmaceutical company focused on
rheumatology and dermatology in the PRC; Haizi, a company engaged
in the manufacture, marketing and sale of inositol and its
by-product, di-calcium phosphate; Natural Dailyhealth, a company
engaged in production and sales of plant extracts for use as key
active ingredients in healthcare products; and Botai, a company
engaged in collagen products.
The Group employs approximately 2,000 people across the PRC,
including over 30 specialist corporate and business development
staff based at the holding company's offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment. For more information
please visit the Company's website: www.cathay-intl.com.hk.
About Lansen
Lansen, whose shares are listed on the mainboard of the Hong
Kong Stock Exchange, is a 50.56% owned subsidiary of Cathay. Lansen
is engaged in the manufacture, distribution and development of
specialty prescription drugs for treatment of autoimmune disorder
in rheumatology and dermatology. Lansen is in the leading market
position in disease modifying anti-rheumatic drugs ("DMARDs") for
treatment of rheumatoid arthritis ("RA") in the PRC. Lansen has
established an extensive distribution network, covering more than
1,000 hospitals in four municipalities, 25 provinces and cities in
the PRC. For more information please visit the Lansen's website:
http://www.lansen.com.cn/en/index.aspx.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR SEDSAWFASEID
(END) Dow Jones Newswires
March 27, 2018 04:59 ET (08:59 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2024 to May 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From May 2023 to May 2024